A Phase 1 Multiple-Ascending-Dose Study to Assess the | Clinical Research Studies Listing

Recruiting

99 years or below

All

1 Location

Brief description of study

This is a first in human, phase 1 trial of BIIB105, which is a novel ASO, in patients with Amyotrophic lateral sclerosis (ALS) and ALS associated with ataxin-2 (ATXN2) poly-CAG expansion (polyQ-ALS). BIIB105 will be administered via fluoro-guided LP up to 5 times over approximately 3 months. Subjects will undergo blood draws, physical examination, pulmonary and strength testing and will complete questionnaires. PolyQ-ALS (Cohort D2) must complete a Natural History Run-in Period prior to dosing.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 11 May 2022. Study ID: 843811

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety Tolerability and Pharmacokinetics of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the Ataxin-2 Gene

Brief description of study

Eligibility of study

Find a site

Interested in the study